Category

• Pipeline2
• Business1
• Research1

Organizations

• Bausch + Lomb46
• Eyes On Eyecare33
• American Optometric Association25
• Alcon, Inc.23
• Glaukos20
• Harrow20
• Aldeyra Therapeutics16
• Ocuphire Pharma16
• Sight Sciences16
• American Academy Of Ophthalmology15

Tags

• Gene Therapy3
• Retina3
• Clinical Trials2
• Inherited Retinal Disease2
• FDA1
• Acquisitions1
• Genetic Testing1
• Injections1
• Leber Congential Amaurosis (lca)1
• Pediatrics1

• organizations:Opus Genetics✕

Clear all

Business

Ocuphire Pharma just purchased Opus Genetics

Operating under the name “Opus Genetics,” the combined company features a pipeline of IRD-targeted gene therapy candidates.

Pipeline

FDA grants Opus Genetics Rare Pediatric Disease Designation for LCA gene therapy

Designation qualifies OPGx-LCA5 to receive a priority review voucher, if approved.

Research

Foundation Fighting Blindness grants Opus Genetics $1.7M to fund IRD programs

Project-based funding will support the advancement of two preclinical trials targeting retinitis pigmentosa.

Pipeline

Opus Genetics acquires rights to Iveric Bio gene therapy candidates

Deal builds on the company’s existing portfolio of AAV-based gene therapies for inherited retinal diseases.